KF-0210 / Keythera Pharma - LARVOL DELTA

A Study of KF-0210 in Advanced Solid Tumors Patients (clinicaltrials.gov) - P1 | N=14 | Completed | Sponsor: Keythera Pharmaceuticals (Australia) Pty Ltd | Recruiting ➔ Completed | N=64 ➔ 14

Enrollment change • Trial completion • Bladder Cancer • Colorectal Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • PD-L1

Discovery of EP4 receptor antagonist KF-0210 for the treatment of cancers (AACR 2023) - "Oral administration of KF-0210 showed superior plasma exposure in rats and mice compared to E7046, another EP4 antagonist under clinical development. KF-0210 is a potent and selective EP4 antagonist with a good PK and safety profile. It shows the inhibitory effect on tumor growth in mouse models of colorectal and breast cancers. The combination treatment of KF-0210 and PD-1/PD-L1 antibodies shows a superior therapeutic effect compared to the monotherapy of each treatment."

Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • TNFA

Keythera first doses KF-0210 in Phase I study, closes USD 15.3m Series A+ funding (GBI Health) - "Suzhou-based Keythera Pharmaceuticals announced first patient dosing with candidate drug KF-0210 in a Phase I clinical study in Australia. The first-in-human study is designed to assess the safety, tolerability, and pharmacokinetics of KF-0210, as well as preliminary efficacy. The targeted indication was undisclosed."

Trial status • Oncology

A Study of KF-0210 in Advanced Solid Tumors Patients (clinicaltrials.gov) - P1; N=64; Not yet recruiting; Sponsor: Keythera Pharmaceuticals (Australia) Pty Ltd

Clinical • New P1 trial • Bladder Cancer • Colorectal Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Urothelial Cancer

A Study of KF-0210 in Advanced Solid Tumors Patients (clinicaltrials.gov) - P1; N=64; Recruiting; Sponsor: Keythera Pharmaceuticals (Australia) Pty Ltd; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Bladder Cancer • Colorectal Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Urothelial Cancer • ALB • CD8 • CXCL10 • PD-L1 • TNFA